Simultaneously, our findings highlight that a more granular understanding of IFNγ signaling (or modulation thereof) will be necessary to fully exploit the anti-tumor effects of STUB1 inhibition, in combination with ICB treatment. The gene discussed is STUB1; the disease is neoplasm.